We are live on ! Find out more
VRCA icon

Verrica Pharmaceuticals
VRCA

40 hedge funds and large institutions have $97M invested in Verrica Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 18 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 4

41% more capital invested

Capital invested by funds: $68.8M → $97M (+$28.2M)

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

0.14% more ownership

Funds ownership: 3.29% → 3.43% (+0.14%)

0% more funds holding

Funds holding: 40 → 40 (0)

Holders
40
Holders Change
–
Holders Change %
0%
% of All Funds
0.87%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
18
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$2.49M
2
KCM
Kornitzer Capital Management
Kansas
+$1.38M
3
Bank of America
Bank of America
North Carolina
+$945K
4
EIM
Essex Investment Management
Massachusetts
+$596K
5
Northern Trust
Northern Trust
Illinois
+$464K

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$791K
2
PVI
Pura Vida Investments
New York
-$521K
3
Morgan Stanley
Morgan Stanley
New York
-$159K
4
JP Morgan Chase
JP Morgan Chase
New York
-$115K
5
UBS Group
UBS Group
Switzerland
-$23.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$38.5M – – –
O
2
OrbiMed
New York
$16M – – –
FI
3
Fosun International
China
$8.59M – – –
Fidelity Investments
4
Fidelity Investments
Massachusetts
$6.72M – – –
BlackRock
5
BlackRock
New York
$5.23M +$2.49M +21,609 +81%
KCM
6
Kornitzer Capital Management
Kansas
$4.84M +$1.38M +11,992 +37%
Vanguard Group
7
Vanguard Group
Pennsylvania
$4.66M +$300K +2,601 +6%
GGHC
8
Gilder Gagnon Howe & Co
New York
$2.53M +$7.84K +68 +0.3%
Point72 Asset Management
9
Point72 Asset Management
Connecticut
$1.59M +$199K +1,722 +13%
CI
10
Conning Inc
Connecticut
$1.4M – – –
Northern Trust
11
Northern Trust
Illinois
$1.16M +$464K +4,018 +60%
Bank of America
12
Bank of America
North Carolina
$921K +$945K +8,192 +2,475%
State Street
13
State Street
Massachusetts
$918K +$28.1K +244 +3%
ACM
14
Asymmetry Capital Management
California
$762K +$87.4K +758 +12%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$665K +$285K +2,467 +67%
EIM
16
Essex Investment Management
Massachusetts
$559K +$596K +5,167 New
PCM
17
Prelude Capital Management
New York
$284K +$303K +2,629 New
Charles Schwab
18
Charles Schwab
California
$282K +$174K +1,511 +138%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$275K +$101K +875 +53%
California State Teachers Retirement System (CalSTRS)
20
California State Teachers Retirement System (CalSTRS)
California
$180K +$91.1K +790 +90%
Deutsche Bank
21
Deutsche Bank
Germany
$144K +$67.8K +588 +78%
CIAS
22
Capital Investment Advisory Services
North Carolina
$134K – – –
RhumbLine Advisers
23
RhumbLine Advisers
Massachusetts
$111K +$118K +1,025 New
BMO
24
Beck Mack & Oliver
New York
$108K – – –
AIG
25
American International Group
New York
$74K +$35.1K +304 +80%
1
2

VRCA Hedge Fund Activity: Q1 2019 in Review

40 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q1 2019, worth a combined $97M — up 41% from $68.8M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new VRCA positions and 4 closed out — a net gain of 1 holder — while 18 added to existing stakes and 4 trimmed.

The largest buyer was BlackRock, adding an estimated $2.49M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $791K sold.

  • 40 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q1 2019, unchanged from Q4 2018.
  • Funds reported $97M of Verrica Pharmaceuticals stock for Q1 2019, up 41% quarter-over-quarter.
  • 5 funds opened new Verrica Pharmaceuticals positions in Q1 2019 and 4 closed out, a net change of +1 holder.
  • The largest Verrica Pharmaceuticals buyer in Q1 2019 was BlackRock, an estimated $2.49M added.
  • The largest Verrica Pharmaceuticals seller in Q1 2019 was Sphera Funds Management, an estimated $791K sold.

Based on aggregated 13F filings for Q1 2019.